Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Familial Hypercholesterolemia - Heterozygous

Interventions

BIOLOGICAL: lerodalcibep 300 mg Monthly SC

Sponsor

LIB Therapeutics LLC